2026-526953-32-00Not yet recruitingPhase 3
Impact of Semaglutide in Liver Transplant Candidates with Obesity (SOMAL Study): A Prospective Randomized Study.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 2 Oct 2026
Brief summary (registry, in English)
To assess the efficacy and safety of semaglutide in liver transplant candidates in terms of weight loss and metabolic control.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 10 Jul 2026
- Start date
- 2 Nov 2026
- Lead sponsor
- Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia
- Diseases
- High blood pressure, Type 2 diabetes, Obesity
- EU CT number
- 2026-526953-32-00
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 50
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Having received prior treatment with semaglutide within the last 6 months.
- Plan for a multi-organ transplant (e.g. liver-kidney) or a re-transplant.
Other illness
- Absolute contraindication to the use of GLP-1 receptor agonists (personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2).
- Upper gastrointestinal haemorrhage due to oesophageal varices.
- A history of acute or chronic pancreatitis.
- Severe disease-related malnutrition (according to GLIM criteria) or advanced sarcopenia (assessed by bioimpedance analysis: ASMMI: <5 in women and >7 in men).
- Haemodynamic instability or an active, uncontrolled infection.
Lab values
- Advanced chronic kidney disease (GFR <30 mL/min/1.73 m²).
- Type 2 diabetes mellitus with HbA1c ≥8.
Other
- Pregnancy or breastfeeding.
- Currently participating in, or having participated in, another clinical trial in the last 30 days.
- CHILD C liver dysfunction.
- Documented severe gastroparesis.
Who the study is looking for
- Age ≥ 18 years.
- Candidate for a liver transplant (on the active waiting list or being evaluated for inclusion on the list).
- Body Mass Index (BMI) ≥ 30 kg/m², or ≥ 27 kg/m² with at least one metabolic comorbidity (type 2 diabetes mellitus with HbA1c <8, high blood pressure, dyslipidaemia).
- Estimated time on the waiting list sufficient to complete at least 12 weeks of treatment with semaglutide prior to the transplant.
- The patient or their legal representative must sign the study’s informed consent form.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Clinical Hospital Virgen De La Arrixaca | Murcia | Spain | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.